What is Microbot Medical's revenue?

Microbot Medical (MBOT) generated $190.2K in revenue over the trailing twelve months, up 62.4% year over year.

Is Microbot Medical profitable?

Microbot Medical is not currently profitable: it reported a net loss of $14.2M over the trailing twelve months, a -3669.9% net margin.

What is Microbot Medical's earnings per share?

Microbot Medical's diluted EPS over the trailing twelve months is $-0.26.

Where does Microbot Medical's income statement data come from?

Every line is extracted from Microbot Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Microbot Medical MBOT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	——	——	——	——
Total cost of revenue	——	——	——	——
Gross profit	——	——	——	——
Research and development	$6.28M-5.2%	$6.63M+15.8%	$5.72M-26.0%	$7.74M+25.7%
Selling, general and administrative	——	$5M—	——	——
Compensation and benefits	$1.06M-21.6%	$1.35M-3.2%	$1.39M-32.6%	$2.07M+8.1%
Depreciation and amortization	$47K-48.4%	$91K-14.2%	$106K+3.9%	$102K+34.2%
Operating income	-$14.74M-26.8%	-$11.63M-18.0%	-$9.86M+25.8%	-$13.28M-16.9%
Interest expense	$1.29M+606%	$182K+40.0%	$130K—	——
Other income (expense), net	——	——	——	——
Income tax expense	——	——	——	——
Net income	-$13.14M-14.8%	-$11.44M-6.5%	-$10.74M+18.4%	-$13.17M-16.4%
Diluted earnings per share	-$0.29+60.8%	-$0.74+31.5%	-$1.08+40.3%	-$1.81-13.8%
Basic earnings per share	-$0.29+60.8%	-$0.74+31.5%	-$1.08+40.3%	-$1.81-13.8%
Weighted-average shares, diluted	161.5M+165%	61M+56.0%	39.1M—	——
Weighted-average shares, basic	161.5M+165%	61M+56.0%	39.1M+36.9%	28.6M+0.5%
Interest Income (Expense), Nonoperating	$1.29M+606%	$182K-20.2%	$228K+93.2%	$118K+168%
Share-based compensation expense related to employee stock plans	$1.06M-25.8%	$1.43M+2.2%	$1.39M-20.4%	$1.75M+26.4%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——
Bank Guarantee Issued	——	$49K0.0%	$49K-9.3%	$54K+12.5%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	$646K—	——	-$11.06M-77.8%
Deferred Issuance Costs	——	——	——	——
Effective tax rates	$0—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Foreign operations	——	——	——	——
Share-based compensation	——	——	——	——
Finance Lease Principal Payments	——	$16K0.0%	$16K0.0%	$16K0.0%
Gross Proceeds From Cash Fee Percentage	——	——	——	——
Gross Proceeds From Management Fee Percentage	——	——	——	——
Income Tax Reconciliation Foreign Income Tax Rate Differential	-$130K—	——	——	——
Income Tax Reconciliation Income Tax Expenses Benefit At Federal Statutory Income Tax Rate	-$2.76M—	——	——	——
Share-based compensation	$227K—	——	——	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	-$308K—	——	——	——
Increase (Decrease) in Accounts Receivable	——	——	——	——
Increase (Decrease) in Deposit Assets	$737K—	——	——	——
Increase (Decrease) in Inventories	$584K—	——	——	——
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	——	$873K—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$182K+364%	-$69K+89.7%	-$672K—	——
Issuance Costs Not Paid	——	——	——	——
Lease Cost	——	——	——	——
Marketable Securities Unrealized Gain Loss	——	——	——	$12K—
Materials And Subcontractors	-$1.9M+12.3%	-$2.17M+8.3%	-$2.36M—	——
Materials And Subcontractors Expenses	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$86.24M+987%	$7.94M+21.0%	$6.56M+51.7%	$4.32M—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$72.38M-4,809%	$1.54M—	——	-$3.84M—
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$13.05M-47.8%	-$8.83M-3.4%	-$8.53M+26.1%	-$11.55M-23.5%
Net Sales Royalty Percentage	——	——	——	——
Number of operating segments	1—	——	——	——
Number of reportable segments	1—	——	——	——
Operating Lease Payments	——	$219K-22.6%	$283K-17.7%	$344K+4.2%
Other Nonoperating Income	$316K—	——	——	——
Other income, net (Note 6)	——	——	——	-$5K—
Payments to Acquire Marketable Securities	——	——	$10.06M+168%	$3.75M—
Payments to Acquire Property, Plant, and Equipment	$60K+140%	$25K—	——	$84K+21.7%
Payments To Increase Longterm Deposit	——	——	——	——
Payroll And Payroll Related	-$7.44M-38.3%	-$5.38M-46.2%	-$3.68M—	——
Payroll And Payroll Related Expenses	——	——	——	——
Proceeds From Exercise Of Options	$1K—	——	——	——
Proceeds from issuance of shares	——	$7.94M+21.0%	$6.56M+51.7%	$4.32M—
Proceeds from legal settlements	——	——	——	——
Proceeds From Other Equity	——	——	——	——
Proceeds from maturities of marketable securities	$10.6M+154%	$4.18M+44.3%	$2.9M—	——
Revenue From Contract With Customer Excluding Assessed Tax	——	——	——	——
Segment Reporting, Other Segment Item, Amount	——	$2.55M+16.3%	$2.2M—	——
Stock-based compensation	$1.06M-21.6%	$1.35M-3.2%	$1.39M-20.4%	$1.75M+26.4%
Risk-free interest rates, high end of range (as a percent)	——	——	——	——
Risk-free interest rates, low end of range (as a percent)	——	——	——	——
Volatilities, high end of range (as a percent)	——	——	——	——
Volatilities, low end of range (as a percent)	——	——	——	——
Stock Issuance Costs Payable	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	——	——	——	$4.32M—
Stock Issued During Period Value Warrants Exercised	$32.38M—	——	——	——
EBIT	-$14.74M-26.8%	-$11.63M-18.0%	-$9.86M+25.8%	-$13.28M-16.9%
EBITDA	-$14.7M-27.4%	-$11.53M-18.3%	-$9.75M+26.0%	-$13.18M-16.8%
EBITDA	-$14.7M-27.4%	-$11.53M-18.3%	-$9.75M+26.0%	-$13.18M-16.8%
EBIT	-$14.74M-26.8%	-$11.63M-18.0%	-$9.86M+25.8%	-$13.28M-16.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Microbot Medical.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Microbot Medical's revenue?: Microbot Medical (MBOT) generated $190.2K in revenue over the trailing twelve months, up 62.4% year over year.
Is Microbot Medical profitable?: Microbot Medical is not currently profitable: it reported a net loss of $14.2M over the trailing twelve months, a -3669.9% net margin.
What is Microbot Medical's earnings per share?: Microbot Medical's diluted EPS over the trailing twelve months is $-0.26.
Where does Microbot Medical's income statement data come from?: Every line is extracted from Microbot Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.